1,491
Participants
Start Date
June 30, 1997
Primary Completion Date
January 31, 2010
Study Completion Date
January 31, 2010
Docetaxel
intravenous
5-fluorouracil
intravenous
Doxorubicin
intravenous
Cyclophosphamide
intravenous
Sanofi-Aventis Administrative Office, Bridgewater
Sanofi-Aventis Administrative Office, Buenos Aires
Sanofi-Aventis Administrative Office, Vienna
Sanofi-Aventis Administrative Office, São Paulo
Sanofi-Aventis Administrative Office, Laval
Sanofi-Aventis Administrative Office, Prague
Sanofi-Aventis Administrative Office, Cairo
Sanofi-Aventis Administrative Office, Paris
Sanofi-Aventis Administrative Office, Berlin
Sanofi-Aventis Administrative Office, Athens
Sanofi-Aventis Administrative Office, Budapest
sanofi-aventis Administrative office, Netanya
Sanofi-Aventis Administrative Office, Warsaw
Sanofi-Aventis Administrative Office, Porto Salvo
Sanofi-Aventis Administrative Office, Bratislava
Sanofi-Aventis Administrative Office, Midrand
Sanofi-Aventis Administrative Office, Barcelona
Sanofi-Aventis Administrative Office, Bromma
Sanofi-aventis adminsitrative office, Guildford Surrey
Sanofi-aventis administrative office, Montevideo
Lead Sponsor
Cancer International Research Group (CIRG)
OTHER
Sanofi
INDUSTRY